A new era in treatment of brain disorders
One of the most common brain disorders in the United States is major depressive disorder (MDD). Dysfunctional electrical activity in the limbic system, which lies deep in the brain, is one of the factors involved in the development of depression as well as many other disorders. The mainstay of treatment for depression includes therapy, electroconvulsive therapy (ECT), and medications. They are fortunately quite helpful for many patients, but too many are still left behind to suffer with depression. Many patients in this group feel like no one understands, trapped, and even hopeless. We are excited to be part of a new era in the treatment of brain disorders. Not only is this technology FDA approved for the treatment of depression, it is also FDA approved for adjunctive treatment for obsessive compulsive disorder (OCD), and posttraumatic stress disorder (PTSD) FDA approval is in the works. We use a technology patented by the US National Institutes of Health (NIH). This coil has many features that ensure precision of targeting and deeper penetration that other coils do not. Deeper and larger areas of the brain are able to be affected for a more robust response. The coil itself is designed to accommodate for the complex shape of the human head to ensure the best contact possible as magnetic fields can decay quickly per unit of distance. Coil elements are oriented parallel to target bundles, tangential to the head, and close to target brain regions to ensure optimized delivery of each pulse of treatment.